Literature DB >> 12215263

Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection.

Mukesh Kumar1, Aruna K Behera, Richard F Lockey, Jian Zhang, Guraman Bhullar, Cristina Perez De La Cruz, Li-Chen Chen, Kam W Leong, Shau-Ku Huang, Shyam S Mohapatra.   

Abstract

Respiratory syncytial virus (RSV) infection is often associated in infancy with life-threatening bronchiolitis, which is also a major risk factor for the development of asthma. At present, no effective prophylaxis is available against RSV infection. Herein, we describe an effective prophylactic intranasal gene transfer strategy utilizing chitosan-DNA nanospheres (IGT), containing a cocktail of plasmid DNAs encoding all RSV antigens, except L. A single administration of IGT (25 microg/mouse) induces expression of the mRNA and proteins of all antigens in the lung and results in a significant reduction of viral titers and viral antigen load after acute RSV infection of these mice. IGT-administered mice show no significant change in airway reactivity to methacholine and no apparent pulmonary inflammation. Furthermore, IGT results in significant induction of RSV-specific IgG antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and interferon-gamma production in the lung and splenocytes compared with controls. Together, these results demonstrate the potential of IGT against acute RSV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215263     DOI: 10.1089/10430340260185058

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  33 in total

1.  Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles.

Authors:  Jing Chen; Wu-Li Yang; Ge Li; Ji Qian; Jing-Lun Xue; Shou-Kuan Fu; Da-Ru Lu
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

Review 2.  Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.

Authors:  Alicia Fernandez-Fernandez; Romila Manchanda; Anthony J McGoron
Journal:  Appl Biochem Biotechnol       Date:  2011-09-27       Impact factor: 2.926

Review 3.  Pulmonary applications and toxicity of engineered nanoparticles.

Authors:  Jeffrey W Card; Darryl C Zeldin; James C Bonner; Earle R Nestmann
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-18       Impact factor: 5.464

Review 4.  Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases.

Authors:  Azam Bolhassani; Shabnam Javanzad; Tayebeh Saleh; Mehrdad Hashemi; Mohammad Reza Aghasadeghi; Seyed Mehdi Sadat
Journal:  Hum Vaccin Immunother       Date:  2013-10-15       Impact factor: 3.452

5.  Efficient mucosal delivery of optical contrast agents using imidazole-modified chitosan.

Authors:  Bilal Ghosn; Anne L van de Ven; Justina Tam; Ann Gillenwater; Konstantin V Sokolov; Rebecca Richards-Kortum; Krishnendu Roy
Journal:  J Biomed Opt       Date:  2010 Jan-Feb       Impact factor: 3.170

6.  Chitosan Interferon-gamma Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses.

Authors:  Xiaoyuan Kong; Gary R Hellermann; Weidong Zhang; Prasanna Jena; Mukesh Kumar; Aruna Behera; Sumita Behera; Richard Lockey; Shyam S Mohapatra
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

7.  Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection.

Authors:  Gregory H Bird; Sandhya Boyapalle; Terianne Wong; Kwadwo Opoku-Nsiah; Raminder Bedi; W Christian Crannell; Alisa F Perry; Huy Nguyen; Viviana Sampayo; Ankita Devareddy; Subhra Mohapatra; Shyam S Mohapatra; Loren D Walensky
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

Review 8.  Respiratory syncytial virus vaccine development.

Authors:  Yoshihiko Murata
Journal:  Clin Lab Med       Date:  2009-12       Impact factor: 1.935

9.  Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics.

Authors:  Yongjian Liu; Aida Ibricevic; Joel A Cohen; Jessica L Cohen; Sean P Gunsten; Jean M J Fréchet; Michael J Walter; Michael J Welch; Steven L Brody
Journal:  Mol Pharm       Date:  2009 Nov-Dec       Impact factor: 4.939

10.  Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: perspectives and challenges for use in lung diseases.

Authors:  M Howell; C Wang; A Mahmoud; G Hellermann; S S Mohapatra; S Mohapatra
Journal:  Drug Deliv Transl Res       Date:  2013-08-01       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.